pharmaphorum

FEBRUARY 4, 2022

The approval of Novavax’ COVID-19 vaccine in Great Britain could help the country save a “considerable amount of money” if it is used in future booster campaigns, according to the former chair of UK Vaccine Taskforce. Dr Clive Dix said that Nuvaxovid has excellent clinical data and – as a it has good stability at fridge temperatures – could be easily rolled out with the flu vaccine next winter, and should “replace the need to buy more Pfizer and Moderna vaccine.” Nu

Vaccines 98

Vaccines 98

Fierce Healthcare

FEBRUARY 4, 2022

Withings grabs health and fitness app 8fit to dig deeper into consumer-centric tech. rtorrence. Fri, 02/04/2022 - 13:55.

116

116

pharmaphorum

FEBRUARY 4, 2022

Eli Lilly has backed away from plans to file Alzheimer’s drug donanemab in the first quarter of this year, saying the proposal to limit reimbursement of Biogen’s first-to-market Aduhelm has made going down the accelerated approval route all-but pointless. The company has planned to filed for speedy approval of donanemab based on the results of its TRAILBLZAR-ALZ study, in the hope of being allowed by the FDA to make the drug available to patients while its confirmatory TRAILBLAZER-AZ

Insurance Coverage 96

Insurance Coverage Insurance FDA 96

Fierce Healthcare

FEBRUARY 4, 2022

Investment firm will take SOC Telemed private in deal valued at $300M. hlandi. Fri, 02/04/2022 - 11:24.

121

121

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

FEBRUARY 4, 2022

Last year, Bayer launched a project to explore the use of artificial intelligence in clinical trials, working with Finland’s Aalto University to find ways to use the technology to support decentralised trials and streamline the testing process. Now, an extension of the work is starting that will see if AI can be used to reduce or remove the need for a control group in some clinical trials , for example in rare diseases where there may be ethical issues in giving an inactive treatment.

Hospitals 69

Hospitals 69

Fierce Healthcare

FEBRUARY 4, 2022

CEO Jain: How SCAN Health Plan went 'viral' during Medicare open enrollment. pminemyer. Fri, 02/04/2022 - 14:05.

110

110

Fierce Healthcare

FEBRUARY 4, 2022

Hospital CEOs: Workforce shortages outweigh financials as top concern in 2021. dmuoio. Fri, 02/04/2022 - 13:46.

Hospitals 110

Hospitals 110

NICE

FEBRUARY 4, 2022

Following the announcement last year of a two-year collaboration agreement between NICE and the AHSN Network , I wanted to consider the alignment between the two organisations and specific ways this agreement looks to further strengthen the use of the best evidence-based healthcare in the NHS. NICE and the AHSN Network share the common purpose of identifying and accelerating the uptake of well-evidenced innovations into health and care services to improve quality, safety, outcomes and experience

52

52

Fierce Healthcare

FEBRUARY 4, 2022

HHS reinforces requirements for providers to give equal care to people with disabilities. rking. Fri, 02/04/2022 - 16:11.

105

105

Pharma Tutor

FEBRUARY 4, 2022

Pharmacy Bill: a Kaleidoscope. Dr. R. S. Thakur. Chief Editor, Journal of Pharmaceutical Research. Krupanidhi College of Pharmacy, Bengaluru-560035. Email: drramsthakur@gmail.com. . admin. Fri, 02/04/2022 - 14:11. Tags. Articles.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharma Mirror

FEBRUARY 4, 2022

Rockville, Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its role as a Data Coordinating Center on a team whose work has accelerated pediatric COVID-19 research through the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02).

52

52

pharmaphorum

FEBRUARY 4, 2022

Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for autoimmune disease generalised myasthenia gravis (gMG) this year, after its C5 inhibitor zilucoplan hit the mark in a phase 3 trial. Zilucoplan achieved a significant improvement in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score compared to placebo at week 12 in the RAISE trial, which UCB said was a “clinically meaningful” result.

FDA 52

FDA 52

Pharma Times

FEBRUARY 4, 2022

Pharma giant Sanofi continues to modernise with branding which reflects its commitment to social responsibility and sustainability

42

42

pharmaphorum

FEBRUARY 4, 2022

In this second article of a three-part series exploring pricing in Europe, CRA’s Life Sciences Practice team discusses the role that disease rarity plays in reimbursement decisions among payers in England, comparing assessments by NICE versus the NHS. Decision makers in the healthcare industry including payers, especially those who rely on the use of cost-effectiveness analysis (CEA) to evaluate new drugs, are often criticised for failing to capture the holistic value of drugs in their health te

97

97

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharma Times

FEBRUARY 4, 2022

Health and social care secretary will declare war on cancer with a decade-long plan to combat disease misery

42

42

pharmaphorum

FEBRUARY 4, 2022

NHS England has agreed a confidential deal with Orchard Therapeutics that will allow access to Libmeldy – a gene therapy for a rare childhood disease that is thought to be the most expensive drug in the world. Libmeldy (atidarsagene autotemcel) was approved by the European Commission to treat metachromatic leukodystrophy (MLD) in December 2020, and subsequently rejected for NHS use by NICE last July on the grounds that it was too expensive – even at the discount offered at the time – and had unc

Compounding 97

Compounding 97